The Lymphoma Research Foundation Awards More Than $2 Million in Grants

Share Article

Grants to Support Follicular and Mantle Cell Lymphoma Research

The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted to funding innovative lymphoma research – announced today that it has awarded $2.15 million in grants to eight U.S. and European scientists investigating new treatments for lymphoma. The grants provide critical support for projects aimed at gaining a better understanding of follicular and mantle cell lymphomas.

“These grants emphasize the Foundation’s commitment to ensuring that the brightest research minds are able to pursue a cure for each of the specific types of lymphoma,” said Diane Blum, LRF Chief Executive Officer. “We remain grateful for our supporters, whose continued confidence in our organization and the LRF mission sustains this important work.”

Recommendations for research funding were made by the LRF Scientific Advisory Board, which is comprised of the world’s leading lymphoma researchers and oncologists. The award recommendations were then approved by the LRF Board of Directors. Grantees include:

Follicular Lymphoma Clinical Awards ($450,000 per award over three years)
John (Wing) Chan, MD
Board of Regents of the University of Nebraska Medical Center
Oncogenic mutations in follicular and transformed follicular lymphoma

Laurence Cooper, MD
University of Texas M.D. Anderson Cancer Center
Off-The-Shelf Immunotherapy For Follicular Lymphoma Infusing CD19-Specific T Cells

David Frank, MD, PhD
Dana-Farber Cancer Institute
Identification and Targeting of Transcription Factor Pathways Activated in Follicular Lymphoma

Mantle Cell Lymphoma (MCL) Developmental/Exploratory Awards ($200,000 per award over two years)
Elias Campo, MD
Institute for Biomedical Research August Pi i Sunyer (Barcelona, Spain)
Identification of Somatic Mutations in Mantle Cell Lymphoma Using Next Generation Sequencing

Samuel Katz, MD, PhD
Dana-Farber Cancer Institute
Reactivating Apoptosis in Mantle Cell Lymphoma by Peptide Replacement of the Tumor Suppressor BIM

Izidore Lossos, MD
Miller School of Medicine of the University of Miami
New Immunotherapeutic Approaches to Mantle Cell Lymphoma

Thomas Tedder, PhD
Duke University Medical Center
Molecular Insights into MCL Immunotherapy

“The research supported by these grants will result in a better understanding of the differences among lymphomas, allowing for the development of more effective and less toxic personalized approaches,” said Bruce Cheson, MD, FACP, FAAAS Professor of Medicine, Head of Hematology, and Deputy Chief of Hematology and Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital and Chair of the LRF Scientific Advisory Board.

For more information about lymphoma, or the LRF research portfolio, visit the LRF website: http://www.lymphoma.org.

About the Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. LRF's mission is to eradicate lymphoma and serve those touched by this disease. LRF remains dedicated to finding a cure for lymphoma through an aggressively-funded research program and by supporting the development of improved therapies for people living with lymphoma. To date, the Foundation has awarded more than $47 million in lymphoma-specific research. The Foundation also provides a comprehensive series of programs and services for people with lymphoma, their loved ones and caregivers.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peggy Ann Torney
Visit website

Media